Emily Clair McClung, MD, FACOG

Kristen N. Ganjoo is a distinguished sarcoma specialist and medical oncologist based in Palo Alto, California, affiliated with Stanford Health Care. As a professor of medicine, she is recognized for her extensive research and contributions to the field of oncology, particularly in the treatment and understanding of sarcomas. Dr. Ganjoo holds multiple board certifications and has been actively involved in various professional organizations, including the American Society of Clinical Oncology and the National Comprehensive Cancer Network. Her commitment to advancing cancer treatment is reflected in her leadership roles and numerous publications in esteemed medical journals. Generated from the website

My research has focused on rare, monogenetic skin diseases such as Epidermolysis Bullosa (EB) and Gorlin Syndrome (Basal Cell Nevus Syndrome). With my PhD training in basic science, post-doctoral fellowship in clinical research, and residency in dermatology, I am committed to improving the lives of EB patients, to correct their underlying genetic disease and to offer new treatments for their skin and esophageal wounds. I was the PI of the investigator-initiated, Phase 1/2A clinical trial of autologous gene-therapy skin grafts for RDEB (Pz-cel, EB-101, previously called LEAES).

Dr. Wapnir’s work in the field of breast oncology spans clinical and translational research. Her past bench research centered on elucidating the activity of the sodium iodide symporter in lactation and breast cancer. She conducted studies on the impact of breast cancer locoregional recurrences with colleagues from the NSABP (NRG Oncology) Cooperative Oncology Group. Based on these, she co-chaired the CALOR (Chemotherapy for isolated locoregional recurrence of breast cancer) trial, that has since defined the use of systemic therapies for this patient population. Nationally, she has been continuously engaged in clinical trials as a member of the NRG Breast Locoregional Subcommittee and NCI-BOLD Task Force.